Zhi Li

Dr. Zhi Li


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
BLBin Li
Bin Li
YLYang Li
Yang Li
XTXiao-Ying Tian
Xiao-Ying Tian
BLBo-Ning Luo
Bo-Ning Luo
ZLZhi Li
Zhi Li
Gangliocytic paraganglioma (GP) is rare and has been regarded as benign in general with a good prognosis. We present a patient with duodenal GP showing a malignant and lethal clinical course. A 47-year-old male patient was found to have a duodenal tumor and enlarged regional lymph nodes. The patient initially underwent a pancreaticoduodenectomy to resect the tumor and involved lymph nodes completely. Histological and immunohistochemical analyses showed findings typical of GP. However, the distant metastatic lesions in the liver and pelvic cavity were rapidly observed after surgery. The patient underwent chemotherapy and radiotherapy, as well as a second surgery to partly remove the metastatic mass in the pelvic cavity. The histological examination revealed no significant difference in histological features between the primary duodenal tumor and the metastatic pelvic mass. However, the patient finally died of the tumor due to the recurrence of the residual pelvic lesion and increased liver mass. To our knowledge, this is the first report of lethal GP with multifocal metastases. Our case confirms that GP should be regarded as a malignant potential tumor with behavior code of “1”, rather than a benign tumor of “0”.

24 September 2010 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
BLBing Liao
Bing Liao
BZBi‐Ling Zhong
Bi‐Ling Zhong
ZLZhi Li
Zhi Li
XTXiao‐Ying Tian
Xiao‐Ying Tian
YLYang Li
Yang Li
BLBin Li
Bin Li

1 September 2021 in Phytomedicine
Verified
Journal Article
Closed access
DRDefang Ren
Defang Ren
YFYu Fu
Yu Fu
LWLi Wang
Li Wang
JLJianqin Liu
Jianqin Liu
XZXia Zhong
Xia Zhong
ZLZhi Li
Zhi Li

6 April 2025 in Carbohydrate Polymers
Verified
Journal Article
Closed access
QZQianyun Zhao
Qianyun Zhao
YLYubin Liu
Yubin Liu
MLMingxing Li
Mingxing Li
LZLong Zhao
Long Zhao
TWTiangang Wang
Tiangang Wang
XWXu Wu
Xu Wu

7 August 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LZLuan-Jing Zhang
Luan-Jing Zhang
KWKe-Bing Wang
Ke-Bing Wang
LLLong-Shan Liu
Long-Shan Liu
LCLian-Zhou Chen
Lian-Zhou Chen
BPBaogang Peng
Baogang Peng
JXJintang Xia
Jintang Xia
Golgi phosphoprotein 3 (GOLPH3) has been identified as an oncoprotein in various human cancers; however, its role in pancreatic ductal adenocarcinoma (PDAC) is unknown. We examined GOLPH3 expression levels and relationship with survival in patients with PDAC to establish the significance of GOLPH3 in the development and progression of PDAC. Real-time qPCR and Western blotting were performed to analyze the expression levels of GOLPH3 mRNA and protein in paired PDAC tumor and adjacent non-tumor tissues. Immunohistochemistry was used to analyze the expression levels of GOLPH3 protein in paraffin-embedded tissues from 109 cases of PDAC. Univariate and multivariate analyses were performed to identify correlations between the immunohistochemical data for GOLPH3 expression and the clinicopathologic characteristics in PDAC. Expression levels of GOLPH3 mRNA and protein were upregulated in PDAC lesions compared to paired adjacent noncancerous tissues. Expression of GOLPH3 was significantly correlated with clinical stage (P = 0.006), T classification (P = 0.021), N classification (P = 0.049) and liver metastasis (P = 0.035). Patients with high GOLPH3 expression had shorter overall survival times compared to those with low GOLPH3 expression (P = 0.007). Multivariate analysis revealed that GOLPH3 overexpression was an independent prognostic factor in PDAC. Our findings suggest that GOLPH3 expression status may be a potential prognostic biomarker and therapeutic target in PCAC.

19 January 2012 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
QYQing-Xu Yang
Qing-Xu Yang
XPXiao-Juan Pei
Xiao-Juan Pei
XTXiao-Ying Tian
Xiao-Ying Tian
YLYang Li
Yang Li
ZLZhi Li
Zhi Li
Only a few cases of extranodal Epstein-Barr virus (EBV)-associated B-cell lymphomas arising from patients with angioimmunoblastic T-cell lymphoma (AITL) have been described. We report a case of AITL of which secondary cutaneous EBV-associated diffuse large B-cell lymphoma (DLBCL) developed after the initial diagnosis of AITL. A 65-year-old Chinese male patient was diagnosed as AITL based on typical histological and immunohistochemical characteristics in biopsy of the enlarged right inguinal lymph nodes. The patient initially received 6 cycles of chemotherapy with CHOP regimen (cyclophosphamide, vincristine, adriamycin, prednisone), but his symptoms did not disappear. Nineteen months after initial diagnosis of AITL, the patient was hospitalized again because of multiple plaques and nodules on the skin. The skin biopsy was performed, but this time the tumor was composed of large, polymorphous population of lymphocytes with CD20 and CD79a positive on immunohistochemical staining. The tumor cells were strong positive for EBER by in situ hybridization. The findings of skin biopsy were compatible with EBV-associated DLBCL. CHOP-R chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) was then administered, resulting in partial response of the disease with pancytopenia and suppression of cellular immunity. To our knowledge, this is the first case of cutaneous EBV-associated DLBCL originated from AITL in Chinese pepole. We suggest the patients with AITL should perform lymph node and skin biopsies regularly in the course of the disease to detect the progression of secondary lymphomas. Virtual slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1197421158639299